Inreda integrates the CGM, [1] has more details on the setup.
> I'm very familiar with one of the most popular, closed-loop system combinations in the USA and I definitely don't feel the hypoglycemia problem is anywhere near "solved".
I should have been clearer, the moderate to severe hypoglycemia (level 2 and 3) problem is essentially solved with the newest generation of closed loop systems. Hypoglycemia in general is trending towards being solved particularly with the newest Medtronic devices, both from studies and what endocrinologists are seeing.
In some of the recent studies (which again are still small as these devices are new) I've come across there are no severe hypo episodes reported and % time in moderate hypoglycemia was (picking one study) ~0.3%[2].
The belief is that further iterations of these algorithms will continue to improve this hence why I said "solved" as in there is no strong need for a large treatment paradigm shift on the basis of moderate-severe hypoglycemia.
> There is too much volatility dictating a person's insulin sensitivity that even today's smartest systems will regularly give too much insulin, requiring treatment, or too little, resulting in prolonged hyperglycemia.
Hyperglycemia is a different discussion altogether that is not addressed by insulin delivery suspension or glucagon. The MiniMed 780G is probably the most advanced system out there with minimal patient input and time in target range is being reported as ~80% which is certainly getting there.
> I'm very familiar with one of the most popular, closed-loop system combinations in the USA and I definitely don't feel the hypoglycemia problem is anywhere near "solved".
I should have been clearer, the moderate to severe hypoglycemia (level 2 and 3) problem is essentially solved with the newest generation of closed loop systems. Hypoglycemia in general is trending towards being solved particularly with the newest Medtronic devices, both from studies and what endocrinologists are seeing.
In some of the recent studies (which again are still small as these devices are new) I've come across there are no severe hypo episodes reported and % time in moderate hypoglycemia was (picking one study) ~0.3%[2].
The belief is that further iterations of these algorithms will continue to improve this hence why I said "solved" as in there is no strong need for a large treatment paradigm shift on the basis of moderate-severe hypoglycemia.
> There is too much volatility dictating a person's insulin sensitivity that even today's smartest systems will regularly give too much insulin, requiring treatment, or too little, resulting in prolonged hyperglycemia.
Hyperglycemia is a different discussion altogether that is not addressed by insulin delivery suspension or glucagon. The MiniMed 780G is probably the most advanced system out there with minimal patient input and time in target range is being reported as ~80% which is certainly getting there.
[1] https://diabetesjournals.figshare.com/articles/figure/Fully_...
[2] https://www.nejm.org/doi/10.1056/NEJMoa2004736?url_ver=Z39.8...